Objective: The value of antiangiogenic inhibitors for patients with recurrent ovarian cancer has not been completely affirmed. Therefore, we aimed to assess the effectiveness and toxicities of various antiangiogenic drugs for the treatment of recurrent ovarian cancer.
Methods: In this meta-analysis, we searched PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials databases for complete randomized controlled trials. The searches were extended to May 15, 2016. The risk of bias of the included studies was evaluated via a Cochrane systematic evaluation, and the statistical analyses were performed using RevMan 5.2 software.
Results: In total, we included 8 randomized controlled trials involving 3,211 patients and divided them into 3 groups, vascular endothelial growth factor receptor inhibitors (VEGFRIs), vascular endothelial growth factor (VEGF) inhibitors (bevacizumab), and angiopoietin inhibitors (trebananib). The progression-free survival improved significantly in all the groups being given antiangiogenic drugs (hazard ratio [HR]: 0.55, 95% confidence interval [CI]: 0.45-0.67, =0%, <0.00001 for the VEGFRI group; HR: 0.53, 95% CI: 0.45-0.63, =51%, <0.00001 for the VEGF inhibitor group; HR: 0.67, 95% CI: 0.58-0.77, =0%, <0.00001 for the trebananib group). Overall survival was obviously prolonged in the VEGFRI (HR: 0.76, 95% CI: 0.59-0.97, =0%, =0.03), the VEGF inhibitor (HR: 0.87, 95% CI: 0.77-0.99, =0%, =0.03), and trebananib groups (HR: 0.81, 95% CI: 0.67-0.99, =0%, =0.04). The incidence of grade 3/4 side effects was different among the 3 groups, for example, proteinuria, hypertension, gastrointestinal perforation, and arterial thromboembolism were presented in the VEGF inhibitor group. Increased incidences of fatigue, diarrhea, and hypertension were seen in the VEGFRI group, and the trebananib group had a higher incidence of hypokalemia.
Conclusion: This meta-analysis showed that antiangiogenic drugs improved the progression-free survival. The VEGFRI, bevacizumab, and trebananib groups showed increased overall survival. Adding antiangiogenic drugs to chemotherapy treatment resulted in a higher incidence of grade 3/4 side effects, but these were manageable.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322854 | PMC |
| http://dx.doi.org/10.2147/OTT.S119879 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lung fibrosis, characterized by chronic and progressive scarring, has no cure. Hallmarks are the accumulation of myofibroblasts and extracellular matrix, as well as vascular remodeling. The crosstalk between myofibroblasts and vasculature is poorly understood, with conflicting reports on whether angiogenesis and vessel density are increased or decreased in lung fibrosis.
View Article and Find Full Text PDFType IV collagen derived non-collagenous domain α6 (IV) NC1 and its derivative fragments inhibit endothelial cell proliferation and attenuates chorioallantoic membrane angiogenesis.
Cytotechnology
April 2025
Department of Genetics, Osmania University, Hyderabad, Telangana State India.
Targeting tumor angiogenesis with safe endogenous protein inhibitors is a promising therapeutic approach despite the plethora of the first line of emerging chemotherapeutic drugs. The extracellular matrix network in the blood vessel basement membrane and growth factors released from endothelial and tumor cells promote the neovascularization which supports the tumor growth. Contrastingly, small cleaved cryptic fragments of the C-terminal non collagenous domains of the same basement membrane display antiangiogenic effect.
View Article and Find Full Text PDFKnowledge and Awareness of Medication-Related Osteonecrosis of the Jaw Among Dental Practitioners in Mumbai: A Questionnaire-Based Survey.
Cureus
December 2024
Oral Pathology and Microbiology, Bharati Vidyapeeth (Deemed to be University) Dental College and Hospital, Navi Mumbai, IND.
Introduction: Osteonecrosis of the jaw resulting from the adverse effects of medical treatments is known as medication-related osteonecrosis of the jaws (MRONJ). The knowledge of dental professionals about this condition is crucial in addressing it on a regional and global scale. This study aims to assess the knowledge and awareness of MRONJ among dental practitioners in Mumbai.
View Article and Find Full Text PDFAssociation of VEGFR2 Polymorphisms with Clinical Outcomes of Anti-angiogenesis Therapy in Cancer Patients: A Systematic Review and Meta-analysis.
Eur J Pharmacol
January 2025
Department of Pharmacy, General Hospital of Northern Theater Command, Shenyang 110840, China; Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China. Electronic address:
Background: Some cancer patients derive limited benefit from anti-angiogenic therapy or discontinuation due to adverse reactions. Vascular endothelial growth factor receptor 2 (VEGFR2) plays an important role in regulating angiogenesis in tumors. This study aims to evaluate the association of VEGFR2 polymorphisms with clinical outcomes of anti-angiogenic drugs (AADs) in cancer patients.
View Article and Find Full Text PDFNew molecular hybrids integrated with quinoxaline and pyrazole structural motifs: VGFR2 inhibitors and apoptosis inducers.
Bioorg Chem
January 2025
Department of Chemistry, Faculty of Science, Al-Azhar University, Cairo 11754 Egypt.
The vascular endothelial growth factor receptor is essential for the angiogenesis of cancer. Tumor propagation was effectively suppressed by inhibiting VEGFR-2 activity. As a result, the target quinoxaline-pyrazole hybrids were created in a way that closely resembled the structural characteristics of VEGFR-2 inhibitors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!